Webcast Alert: Platinum Resistance in Ovarian Cancer

SYDNEY, Australia and NEW CAANAN, Conn., Nov. 9 Asymposium on platinum resistant ovarian cancer held at the European Societyfor Gynecological Oncology in Berlin on Sunday, 28 October has confirmed theneed for an effective chemosensitizing drug to support new platinum treatmentregimens in resistant ovarian cancer. Leading cancer researchers speaking atthe symposium described advances in platinum therapies and reviewed data onphenoxodiol, an investigational drug that researchers hope to find willresensitize ovarian cancer patients to chemotherapy. Medical professionalswho treat patients with recurrent ovarian cancer are encouraged to view thisfree Webcast.

About Marshall Edwards, Inc.:

Marshall Edwards, Inc. (Nasdaq: MSHL) is a specialist oncology companyfocused on the clinical development of novel anti-cancer therapeutics. Thesederive from a flavonoid technology platform, which has generated a number ofnovel compounds characterized by broad ranging activity against a range ofcancer cell types with few side effects. The combination of anti-tumor cellactivity and low toxicity is believed to be a result of the ability of thesecompounds to target an enzyme present on the surface of cancer cells, therebyinhibiting the production of pro-survival proteins within the cell. MarshallEdwards, Inc. has licensed rights from Novogen Limited (Nasdaq: NVGN) to bringthree oncology drugs -- phenoxodiol, NV-196 and NV-143 -- to market globally.The Company's lead investigational drug, phenoxodiol, is in a Phase IIImultinational multi-centered clinical trial for patients with recurrentovarian cancer. More information on the trial can be found athttp://www.OVATUREtrial.com.

Marshall Edwards, Inc. is majority owned by Novogen, an Australianbiotechnology company that is specializing in the development of therapeuticsbased on a flavonoid technology platform. Novogen, based in Sydney, Australia,is developing a range of therapeutics across the fields of oncology,cardiovascular disease and inflammatory diseases. More information onphenoxodiol and on the Novogen group of companies can be found atwww.marshalledwardsinc.com and www.novogen.com.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free fromhttp://www.microsoft.com and at least a 56Kbps connection to the Internet.

If you experience problems listening to the webcast, send an E-mail to:[email protected]: Platinum Resistance in Ovarian Cancer When: Available Now Where: www.ovaturetrial.com/esgosymposium How: On the Internet -- Simply log on to the web at the address above. Contact: David Sheon Chris Naughton 202-518-6321 011 61 2 9878 0088 [email protected] [email protected]

SOURCE Marshall Edwards, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...